SCHEMBL6787909

SCHEMBL6787909

CC(=O)Nc1ccc(C(=O)O)c(NC(=O)CC(C)c2ccc3ccccc3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ HCRTR1 O43613 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GRIK1 P39086 1/20 0.47
▸ GRIK2 Q13002 1/20 0.47
▸ SCN3A Q9NY46 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.44
▸ CYP1A2 P05177 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784822 0.91 TDP1 (0.48) RAB9ASMN1; SMN2GAAHCRTR1TDP1
SCHEMBL6789605 0.89 RAB9A (0.49) RAB9ASMN1; SMN2GAATDP1GRIK1
SCHEMBL6781577 0.85 KMT2A (0.58) RAB9ASMN1; SMN2GAAMEN1KMT2A
SCHEMBL6790188 0.82 RAB9A (0.47) RAB9ASMN1; SMN2GAAALDH1A1MEN1
SCHEMBL14349698 0.78 HCAR2 (0.60) MEN1KMT2AKDM4EPOLBCASP3
SCHEMBL14349718 0.76 KDM4E (0.51) MEN1KMT2AKDM4EPOLBCASP3
SCHEMBL14349697 0.76 HCAR2 (0.64) RAB9ASMN1; SMN2ALDH1A1CYP1A2MEN1
SCHEMBL6784915 0.75 KMT2A (0.57) TDP1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL976774 0.74 MPO (0.58) RAB9ASMN1; SMN2TDP1GRIK1ALDH1A1
SCHEMBL11796147 0.72 MPO (0.57) RAB9ASMN1; SMN2TDP1GRIK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 — — US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 — — US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 RAB9A 2130/4885SMN1; SMN2 62/4885GAA 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback